Mathews-Roth M M, Pathak M A, Fitzpatrick T B, Harber L H, Kass E H
Arch Dermatol. 1977 Sep;113(9):1229-32.
We treated with high doses of oral beta carotene (Solatene) (15 to 180 mg/day) 133 patients suffering from erythropoietic protoporphyria (EPP), 27 patients with polymorphous light eruption, six patients with solar urticaria, three patients with hydroa aestivale, one patient with porphyria cutanea tarda, and two patients with actinic reticuloid to relieve the photosensitivity associated with these diseases. Eighty-four percent of the patients with erythropoietic protoporphyria increased by a factor of 3 or more their ability to tolerate sunlight. On the other hand, only nine of the patients with polymorphous light eruption, and one fifth of the patients with all of the other forms of photosensitivity treated showed similar improvement. We conclude that beta carotene is an effective treatment for EPP, but that other forms of photosensitivity will need empirical therapeutic study with beta carotene to determine the range of effectiveness, if any, of this compound in conditions other than EPP.
我们对133例红细胞生成性原卟啉病（EPP）患者、27例多形性日光疹患者、6例日光性荨麻疹患者、3例夏令水疱病患者、1例迟发性皮肤卟啉病患者和2例光化性类网状细胞增多症患者使用大剂量口服β-胡萝卜素（索拉亭）（15至180毫克/天）进行治疗，以缓解与这些疾病相关的光敏性。红细胞生成性原卟啉病患者中有84%耐受阳光的能力提高了3倍或更多。另一方面，多形性日光疹患者中只有9例，以及接受治疗的所有其他形式光敏性患者中有五分之一表现出类似的改善。我们得出结论，β-胡萝卜素是治疗EPP的有效药物，但其他形式的光敏性疾病需要对β-胡萝卜素进行经验性治疗研究，以确定该化合物在EPP以外的疾病中的有效性范围（如果有的话）。
